The ALK receptor in sympathetic neuron development and neuroblastoma

被引：31

作者：

Janoueix-Lerosey, Isabelle ^{[1
,2
]}

Lopez-Delisle, Lucille ^{[1
,3
]}

Delattre, Olivier ^{[1
,2
]}

Rohrer, Hermann ^{[4
]}

机构：

[1] PSL Res Univ, Inst Curie, INSERM, Equipe Labellisee Ligue Canc,U830, F-75005 Paris, France

[2] Inst Curie, SIREDO Care Innovat & Res Children Adolescents &, F-75005 Paris, France

[3] EPFL SV ISREC UPDUB, Lab Dev Gen, SV 2843, CH-1015 Lausanne, Switzerland

[4] Goethe Univ Frankfurt, Inst Clin Neuroanat, Neurosci Ctr, Theodor Stern Kai 7, D-60590 Frankfurt, Germany

来源：

CELL AND TISSUE RESEARCH | 2018年 / 372卷 / 02期

关键词：

ALK; Sympathetic ganglia; Neuroblastoma; Signaling; Targeted therapy; ANAPLASTIC LYMPHOMA KINASE; TYROSINE KINASE; ACTIVATED ALK; TRUNCATED FORM; GROWTH-FACTOR; INHIBITOR PF-06463922; MONOCLONAL-ANTIBODIES; THERAPEUTIC TARGET; IN-VITRO; C-ROS;

D O I：

10.1007/s00441-017-2784-8

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The ALK gene encodes a tyrosine kinase receptor characterized by an expression pattern mainly restricted to the developing central and peripheral nervous systems. In 2008, the discovery of ALK activating mutations in neuroblastoma, a tumor of the sympathetic nervous system, represented a breakthrough in the understanding of the pathogenesis of this pediatric cancer and established mutated ALK as a tractable therapeutic target for precision medicine. Subsequent studies addressed the identity of ALK ligands, as well as its physiological function in the sympathoadrenal lineage, its role in neuroblastoma development and the signaling pathways triggered by mutated ALK. This review focuses on these different aspects of the ALK biology and summarizes the various therapeutic strategies relying on ALK inhibition in neuroblastoma, either as monotherapies or combinatory treatments.

引用

页码：325 / 337

页数：13

共 102 条

[1] A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies [J].

Althoff, K. ;

Beckers, A. ;

Bell, E. ;

Nortmeyer, M. ;

Thor, T. ;

Spruessel, A. ;

Lindner, S. ;

De Preter, K. ;

Florin, A. ;

Heukamp, L. C. ;

Klein-Hitpass, L. ;

Astrahantseff, K. ;

Kumps, C. ;

Speleman, F. ;

Eggert, A. ;

Westermann, F. ;

Schramm, A. ;

Schulte, J. H. .

ONCOGENE, 2015, 34 (26) :3357-3368

[2]

[Anonymous], N ENGL J MED

[3] Frizzled3 Is Required for Neurogenesis and Target Innervation during Sympathetic Nervous System Development [J].

Armstrong, Alissa ;

Ryu, Yun Kyoung ;

Chieco, Deanna ;

Kuruvilla, Rejji .

JOURNAL OF NEUROSCIENCE, 2011, 31 (07) :2371-2381

[4] Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis [J].

Bellini, Angela ;

Bernard, Virginie ;

Leroy, Quentin ;

Frio, Thomas Rio ;

Pierron, Gaelle ;

Combaret, Valerie ;

Lapouble, Eve ;

Clement, Nathalie ;

Rubie, Herve ;

Thebaud, Estelle ;

Chastagner, Pascal ;

Defachelles, Anne Sophie ;

Bergeron, Christophe ;

Buchbinder, Nimrod ;

Taque, Sophie ;

Auvrignon, Anne ;

Valteau-Couanet, Dominique ;

Michon, Jean ;

Janoueix-Lerosey, Isabelle ;

Delattre, Olivier ;

Schleiermacher, Gudrun .

CLINICAL CANCER RESEARCH, 2015, 21 (21) :4913-4921

[5] THE ITK RECEPTOR TYROSINE KINASE IS EXPRESSED IN PRE-B LYMPHOCYTES AND CEREBRAL NEURONS AND USES A NON-AUG TRANSLATIONAL INITIATOR [J].

BERNARDS, A ;

DELAMONTE, SM .

EMBO JOURNAL, 1990, 9 (07) :2279-2287

[6] The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma [J].

Berry, Teeara ;

Luther, William ;

Bhatnagar, Namrata ;

Jamin, Yann ;

Poon, Evon ;

Sanda, Takaomi ;

Pei, Desheng ;

Sharma, Bandana ;

Vetharoy, Winston R. ;

Hallsworth, Albert ;

Ahmad, Zai ;

Barker, Karen ;

Moreau, Lisa ;

Webber, Hannah ;

Wang, Wenchao ;

Liu, Qingsong ;

Perez-Atayde, Antonio ;

Rodig, Scott ;

Cheung, Nai-Kong ;

Raynaud, Florence ;

Hallberg, Bengt ;

Robinson, Simon P. ;

Gray, Nathanael S. ;

Pearson, Andrew D. J. ;

Eccles, Suzanne A. ;

Chesler, Louis ;

George, Rani E. .

CANCER CELL, 2012, 22 (01) :117-130

[7] Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications [J].

Bilsland, James G. ;

Wheeldon, Alan ;

Mead, Andrew ;

Znamenskiy, Petr ;

Almond, Sarah ;

Waters, Kerry A. ;

Thakur, Matthew ;

Beaumont, Vahri ;

Bonnert, Timothy P. ;

Heavens, Robert ;

Whiting, Paul ;

McAllister, George ;

Munoz-Sanjuan, Ignacio .

NEUROPSYCHOPHARMACOLOGY, 2008, 33 (03) :685-700

[8] ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma [J].

Bresler, Scott C. ;

Weiser, Daniel A. ;

Huwe, Peter J. ;

Park, Jin H. ;

Krytska, Kateryna ;

Ryles, Hannah ;

Laudenslager, Marci ;

Rappaport, Eric F. ;

Wood, Andrew C. ;

McGrady, Patrick W. ;

Hogarty, Michael D. ;

London, Wendy B. ;

Radhakrishnan, Ravi ;

Lemmon, Mark A. ;

Mosse, Yael P. .

CANCER CELL, 2014, 26 (05) :682-694

[9] Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma [J].

Bresler, Scott C. ;

Wood, Andrew C. ;

Haglund, Elizabeth A. ;

Courtright, Joshua ;

Belcastro, Lili T. ;

Plegaria, Jefferson S. ;

Cole, Kristina ;

Toporovskaya, Yana ;

Zhao, Huaqing ;

Carpenter, Erica L. ;

Christensen, James G. ;

Maris, John M. ;

Lemmon, Mark A. ;

Mosse, Yael P. .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (108)

[10]

Carpenter EL, 2012, ONCOGENE, V31, P4859, DOI 10.1038/onc.2011.647

← 1 2 3 4 5 6 7 8 9 10 →